




RealRate

PHARMACEUTICAL 2022

IGM Biosciences Inc
Rank 297 of 471



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of IGM Biosciences Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of IGM Biosciences Inc compared to the market average is the variable Liabilities, increasing the Economic Capital Ratio by 61% points. The greatest weakness of IGM Biosciences Inc is the variable Comprehensive Net Income, reducing the Economic Capital Ratio by 79% points.

The company's Economic Capital Ratio, given in the ranking table, is 242%, being 33% points below the market average of 275%.

Input Variable	Value in 1000 USD
Assets, Current	240,747
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	27,780
Liabilities, Non-Current	25,439
Other Assets	28,885
Other Compr. Net Income	-92
Other Expenses	0
Other Liabilities	0
Other Net Income	-165,164
Other Revenues	0
Property and Equipment	28,495
Research and Development	127,026
Selling, General and Administrative Expense	38,297

Output Variable	Value in 1000 USD
Assets	298,127
Liabilities	53,219
Expenses	165,323
Revenues	0
Stockholders Equity	244,908
Net Income	-330,487
Comprehensive Net Income	-330,533
BaseVar	340,962
ECR before Limited Liability	116%
Economic Capital Ratio	242%